Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studySara Y. Tartof, John M. McLaughlin, Srinivas Rao Valluri et al.|The Lancet|2021Cited by 1.3k
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control studySara Y. Tartof, John M. McLaughlin, Jeff Slezak et al.|The Lancet Respiratory Medicine|2022Cited by 152
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort studySara Y. Tartof, John M. McLaughlin, Jeff Slezak et al.|The Lancet Regional Health - Americas|2022Cited by 117
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5Sara Y. Tartof, John M. McLaughlin, Jeff Slezak et al.|The Lancet Infectious Diseases|2022Cited by 77
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control studySara Y. Tartof, John M. McLaughlin, Jeff Slezak et al.|The Lancet Respiratory Medicine|2023Cited by 76